Published DNL343 trial finds no slowing of ALS progression

A randomized trial report published September 22 in JAMA Network Open found that experimental drug DNL343 did not slow amyotrophic lateral sclerosis, or ALS. The publication adds clinical detail to an important test of whether targeting cellular stress can preserve neurological function.

The chronology matters: Denali Therapeutics first announced the unsuccessful primary outcome on January 6, 2025. This week’s development is the peer-reviewed report, rather than a newly disclosed trial failure.

### What the trial found

The double-blind study ran at 74 U.S. centers within the HEALEY ALS Platform Trial. Investigators compared 186 participants assigned DNL343 with 139 placebo participants, including 76 enrolled concurrently in another treatment arm. Mean age was 59.3 years.

The primary endpoint combined functional decline and survival over 24 weeks. The estimated disease-rate ratio was 1.04, with a 95% credible interval of 0.83–1.32; values below 1 would favor treatment. The result did not establish benefit.

Serious adverse events occurred in 15.1% of DNL343 recipients and 11.5% of shared placebo recipients. Investigators attributed three serious events to DNL343. These findings should not be compressed into an unqualified claim that the drug was safe.

### Why researchers tested cellular stress

DNL343 is a small molecule designed to activate eIF2B, a protein complex involved in controlling protein production. Its intended effect is to dampen the integrated stress response, a cellular program implicated in ALS biology.

Earlier research, published in 2025, combined laboratory experiments with initial human studies. In experimental systems involving TDP-43, a protein associated with ALS pathology, compounds acting through this pathway reduced stress-response signals. A related compound temporarily delayed movement problems and neurodegeneration in a mouse model.

Early randomized human testing primarily examined safety and tolerability. It also supplied evidence that DNL343 reached the central nervous system and affected pathway-related biomarkers. Those observations supported moving into a larger efficacy trial, but they could not establish that patients would retain abilities or live longer.

For healthspan research, that distinction is central. A measurable biological response can help researchers determine whether a drug reaches its intended target. Demonstrating that the response translates into meaningful function requires a separate clinical test.

### What was already known

Denali’s January 2025 announcement reported that the trial missed its primary endpoint and found no statistically significant differences in key measures of muscle strength and respiratory function.

In its first-quarter 2025 update, the company subsequently reported no treatment effect on neurofilament light, a marker of neuronal damage, during the controlled period or in a subset followed during an extension. Denali said the active-treatment extension had been discontinued. Those decisions predate the new publication and should not be presented as September 2026 actions.

### How far the conclusion extends

The controlled period lasted six months, and 92.6% of participants were White, limiting duration and population coverage. The result addresses this treatment strategy in the studied ALS population.

It does not establish that every intervention targeting cellular stress will fail, nor does it demonstrate an effect on normal aging. Conversely, mechanistic plausibility and encouraging early biomarkers cannot substitute for the missing clinical benefit.

The practical contribution is a clearer evidentiary boundary: this program generated reasons to test a biological hypothesis, but the randomized efficacy trial did not establish that DNL343 preserved function or improved survival.